GC-072

GC-072 (0.25 μg/mL, 2.5 μg/mL; 0, 1, 5, 24 hours) effectively inhibits the growth of intracellular B. pseudomallei in murine macrophage cells in a rapid time- and dose-dependent manner, with no viable bacteria detectable after 24 hours at either concentration^[1].
GC-072 inhibits both E.coli and S. aureus gyrase and Topo IV. The IC₅₀ values of 2 μM, 0.18-1.50 μM, 4-30 μM, and 4.22-8.45 μM for S. aureus gyrase, E.coli gyrase, S. aureus Topo IV, and E.coli Topo IV, respectively^[1].
GC-072 demonstrates good activity against B. pseudomallei, with an MIC₉₀ of 0.25 μg/mL and a range of ≤0.008 to 1 μg/mL^[1].
The MIC90s of GC-072 against B. anthracis, Y. pestis, F. tularensis, and B. mallei are 0.002 μg/mL, 0.015 μg/mL, ≤0.0005 μg/mL, and 0.12 μg/mL, respectively^[1].
GC-072 is fully active against the panel of drug-resistant B. pseudomallei strains tested (i.e., Ceftazidime (HY-B0593)-, Clavulanate (HY-A0256A)- and Trimethoprim (HY-B0510)-resistant strains)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.